WTX-330, a conditionally activated IL-12 INDUKINE™ therapy, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models

Kristin Morris, Heather R. Brodkin, Daniel J. Hicklin, Nesreen Ismail, Christopher J. Nirschl, Andres Salmeron, Cindy Seidel-Dugan, Philipp Steiner, Zoe Steuert, Jenna M. Sullivan and William M. Winston

Werewolf Therapeutics, Cambridge, Massachusetts, USA

#715

INTRODUCTION

- Systemic therapy with proinflammatory immune modulators is a promising approach for treating cancer
  - The cytokine interleukin-12 (IL-12) is a potent inducer of innate and adaptive anti-tumor immunity, but there are currently no approved IL-12 therapies available
  - Unfortunately, high-dose IL-12 treatment is associated with inflammation and tissue damage, which has rendered IL-12 treatment strategies impractical
- WTX-330 is an inducible polypeptide (INDUKINE™ therapies) designed to be an inactive IL-12 pro-drug with a half-life extension domain to support infrequent systemic administration (**Figure 1**)
  - Kept inactive in the periphery via high-affinity antibody blockade tethered to IL-12 via a tumor protease-sensitive linker
  - Designed to minimize the severe toxicities seen with recombinant human IL-12 (rIL-12) therapy and maximize clinical benefit when given alone or in combination with immune checkpoint inhibitors
- WTX-330 is designed to be a first-in-class, systemically delivered, conditionally activated IL-12 INDUKINE™ molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma

Figure 1. Key features of WTX-330



Key features of WTX-330 include peripheral blockade (green) of the IL-12–IL-12 receptor interaction to limit systemic toxicity, half-life extension (blue) for optimal exposure in tumors and conditional activation in the tumor microenvironment.
IL-12, interleukin-12.

RESULTS

PROOF OF CONCEPT

- Three cell-based assays were used to demonstrate inducibility of the cleaved INDUKINE™ molecule, WTX-330, after *in vitro* activation by cleavage of protease-sensitive linkers (**Figure 2**)
- Activity was compared to recombinant chimeric IL-12 (mouse p35, human p40) to ensure cross-reactivity with the mouse/human IL-12 receptor

RESULTS

Figure 2. Cell-based assays show activity of the IL-12 INDUKINE™ molecule (WTX-330)



HEK, human embryonic kidney; IFNγ, interferon gamma; IL-12, interleukin-12; OD, optical density; RLU, relative light units.

ANTI-TUMOR EFFICACY

- WTX-330 mouse surrogate molecule (mouse WTX-330) vs rIL-12 were given to MC38 (colon) tumor mice at equivalent molar doses over the treatment period (**Figure 3**)
  - Both treatments were active, but rIL-12-treated animals were all deceased by Day 11
  - Conversely, mouse WTX-330-treated animals remained well and retained body weight

Figure 3. Mouse WTX-330 vs rIL-12 in MC38 mouse tumor model



*Anti-tumor efficacy was assessed in the MC38 tumor model. Tumor cells were injected subcutaneously. **A**) Tumor growth of MC38 mice treated with mouse WTX-330 (twice weekly for 2 weeks, via IP), vehicle (IP), or rIL-12 at equivalent molar doses over the treatment period (twice daily for 10 days, IP). **B**) Body weight of mouse WTX-330- or rIL-12-treated animals.*
IP, intraperitoneal; rIL-12, recombinant human interleukin-12.

DOSE RESPONSE

- A dose response with mouse WTX-330 in the syngeneic MC38 tumor model showed
  - Mouse WTX-330 induced 100% complete regression in MC38 tumors (**Figure 4A**)
  - The non-cleavable surrogate is much less active than mouse WTX-330 that has a cleavable linker (**Figure 4A**)
  - All dose levels were well tolerated in mice
  - Systemic interferon gamma levels remained low after treatment (**Figure 4B**)

RESULTS

Figure 4. Mouse WTX-330 dose response in MC38 mouse tumor model



IFNγ, interferon gamma; NC, non-cleavable.

IMMUNE MEMORY

- Mouse WTX-330 was shown to induce immune memory in MC38 mice rechallenged with MC38 tumor cells after showing complete regression with WTX-330 (**Figure 5**)

Figure 5. Mouse WTX-330 induces immune memory in MC38 mice



Mice previously treated with mouse WTX-330 and displaying complete regression, alongside naïve age-matched control mice, were rechallenged with MC38 tumor cells.

ANTI-TUMOR EFFICACY IN OTHER MOUSE TUMOR MODELS

- Mouse WTX-330 shows a dose response in the mouse colon CT26 tumor model with no weight loss (**Figure 6A**)
- In the difficult-to-treat B16F10 melanoma model, mouse WTX-330 is efficacious, with tumor regrowth only seen after treatment ended (**Figure 6B**)
- Mouse WTX-330 is efficacious and well tolerated in the less immunogenic EMT-6 model (**Figure 6C**)

Figure 6. Anti-tumor activity of mouse WTX-330 in other mouse tumor models



PLEIOTROPIC IMMUNE RESPONSES

- WTX-330 activates pleiotropic immune responses in MC38 mouse tumors (**Figure 7**)
- WTX-330 treatment amplifies tumor infiltration and induces immune cell activation (**Figures 7A–B**)

RESULTS

Figure 7. Immune profiling analysis of B16 mouse tumors and draining lymph nodes



***A**) WTX-330 leads to preferential T cell activation in the tumor, as compared with DLN. **B**) WTX-330 increases cross-presenting dendritic cell frequencies and function in tumors (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$).*
DCs, dendritic cells; DLN, draining lymph nodes; IFNγ, interferon gamma; IL-12, interleukin-12; MHC I, major histocompatibility complex class I; Tet, tetramer; TIL, tumor-infiltrating lymphocyte; Treg, regulatory T cell.

PHARMACOKINETICS AND TOLERABILITY

- There was an overall increase in exposure (maximum concentration [C_{max}] and area under the curve [AUC]) with increasing dose of mouse WTX-330 in naïve mice (**Figure 8A**)
- The mean half-life of WTX-330 was 53 hours in non-human primates (NHPs) (**Figure 8B**)
- Plasma free IL-12 compared with total IL-12 INDUKINE™ was < 0.1% (**Figure 8C**)
- 6 mg/kg WTX-330 (single and repeat dose) was well-tolerated in Chinese and Mauritian cynomolgus monkeys (**Table 1**)
- Exposure (C_{max}, AUC) was higher in NHPs (given at the tolerated dose of 6 mg/kg) compared with mice (given at the efficacious dose of 0.7 mg/kg) (**Table 1**)

RESULTS

Figure 8. Plasma PK of WTX-330 in mice and cynomolgus monkeys



***A**) PK analysis for total IL-12 (intact mouse WTX-330 combined with free IL-12 [ELISA]) in mouse plasma. **B**) PK analysis for WTX-330 in NHP.*
ELISA, enzyme-linked immunosorbent assay; IL-12, interleukin-12; LLOQ, lower limit of quantification; NHP, non-human primate; PK, pharmacokinetics.

Table 1. PK of WTX-330 in mice and cynomolgus monkeys

	Dose	C_{max} (nM)	AUC (nM*h)	Findings
Mouse	0.7 mg/kg	22.5	811	MC38 tumor growth inhibition
NHP	6 mg/kg	876	33619	Well tolerated in monkeys
Target exposure multiples		39	41.6	

Exposure parameters expressed as C_{max} and AUC, and target exposure multiples comparing highest tolerated exposure in NHPs divided by lowest efficacious exposure in MC38 tumor mice. AUC, area under the curve; C_{max}, maximum concentration; NHP, non-human primate; PK, pharmacokinetics.

CONCLUSIONS

- Proof-of-concept assays of WTX-330 (an IL-12 INDUKINE™ lead molecule) demonstrate anti-tumor activity in syngeneic mouse models and better tolerability compared with rIL-12
- Mouse WTX-330 potently inhibits tumor growth in MC38, CT26, B16F10 and EMT6 mouse tumor models
- Changes in immune profiles in mouse tumors after IL-12 INDUKINE™ therapy support a mechanism of action similar to rIL-12
- WTX-330 is well tolerated in NHPs and reaches C_{max} and AUC exposures far higher than the efficacious exposures seen in mice

ACKNOWLEDGMENTS

The authors were responsible for all content and editorial decisions; editorial support was provided by MediTech Media, funded by Werewolf Therapeutics.

Poster presented at SITC Annual Meeting, Nov. 10–14, 2021; Washington, D.C.